aTyr: Positive Topline Results in Phase 2 Trial in COVID-19 with Severe Respiratory Complications

 Study met primary safety endpoint in moderate to severe hospitalized COVID-19 patients.

A single dose of 3.0 mg/kg of ATYR1923 resulted in a median time to recovery of 5.5 days.

83% of patients receiving 3.0 mg/kg dose of ATYR1923 achieved recovery in less than a week.

Management hosted conference call and webcast January 4 at 5:00pm ET/2:00pm PT. Links to a live audio webcast and replay may be accessed on the aTyr website events page at: http://investors.atyrpharma.com/events-and-webcasts. An audio replay will be available for at least 90 days following the event.

https://finance.yahoo.com/news/atyr-pharma-announces-positive-topline-211500350.html